Publications by authors named "Z Veceric-Haler"
Article Synopsis
- COVID-19 can lead to multiorgan issues, including thrombotic microangiopathy (TMA), which we studied in eight patients at our center.
- Most patients showed few COVID-19 symptoms, and TMA occurred after the virus was present in their system; two had additional non-COVID-related factors triggering TMA.
- Treatments varied based on the type of TMA, with some achieving recovery in blood and kidney functions, highlighting the need for tailored treatment approaches due to different causes and responses.
Article Synopsis
- Many kidney transplant patients are classified as having no rejection after biopsy, but some may actually have undetected rejection activities.
- A study of over 5,000 biopsies found that more than half were marked as no rejection, yet many showed signs of subthreshold T cell-mediated rejection (TCMR) and antibody-mediated rejection (ABMR).
- Patients with these hidden rejection activities are at increased risk of future graft issues, as higher levels of TCMR and ABMR correlate with worse kidney function and higher chances of rejection in subsequent biopsies.
Introduction: MicroRNAs (miRNAs), short noncoding RNAs, are involved in the modulation of gene expression, mainly by inhibiting the translation of mRNAs. Under physiological conditions, miRNAs are involved in viral infections and immune responses, among others; aberrant miRNA expression has been associated with kidney transplant pathologies, but a comprehensive comparison of later, particularly in tissue sections, is still pending.
Methods: We used the genome-wide screening of miRNAs to identify those potentially involved in the disease processes after kidney transplantation.
Mesenchymal stem cell (MSCs) therapy has already been studied in kidney transplant recipients (KTRs), and the available data showed that it is safe and well tolerated. The aim of this study was to evaluate the safety and efficacy of autologous MSCs in combination with standard therapy in KTRs with biopsy-proven chronic active antibody-mediated rejection (AMR). Patients with biopsy-proven chronic active AMR received treatment with autologous bone marrow-derived MSCs (3 × 10 cells/kg iv) after completion of standard therapy and were followed for up to 12 months.
View Article and Find Full Text PDFCoronavirus disease 2019 (COVID-19) can lead to clinically significant multisystem disorders that also affect the kidney. According to recent data, renal injury in the form of thrombotic microangiopathy (TMA) in native kidneys ranks third in frequency. Our review of global literature revealed 46 cases of TMA in association with COVID-19.
View Article and Find Full Text PDF